ArticleNature communications2026
Advanced nanoformulations of NUAK1 regulate NLRP3 inflammasome for preeclampsia management in mice.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is a severe pregnancy complication driven by placental dysfunction and oxidative stress, which currently lacks effective targeted therapies. Here, we evaluated the therapeutic potential of folic acid-modified lipid nanoparticles (NPs) co-loaded with polydopamine and NUAK Family Kinase 1 (NUAK1), termed FLN@(PDA + NUAK1) NPs, for mitigating PE. In vitro, these NPs effectively reduced reactive oxygen species levels and suppressed activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, while promoting autophagic activity and inhibiting apoptosis under oxidative stress. In vivo analysis using an L-NAME-induced PE mouse model further confirmed that FLN@(PDA + NUAK1) NPs improved placental structure and fetal growth parameters. This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.